Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Retained Earnings (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Retained Earnings data on record, last reported at -$513000.0 in Q1 2026.

  • On a quarterly basis, Retained Earnings fell 832.86% to -$513000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$513000.0, a 832.86% decrease, with the full-year FY2025 number at $174000.0, up 100.03% from a year prior.
  • Retained Earnings reached -$513000.0 in Q1 2026 per FULC's latest filing, down from $174000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for FULC hit a ceiling of $241000.0 in Q3 2025 and a floor of -$536.5 million in Q1 2024.
  • A 5-year average of -$191.7 million and a median of -$1.1 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 4027677.78% in 2022, then skyrocketed 122.4% in 2025.
  • Tracing FULC's Retained Earnings over 5 years: stood at -$797000.0 in 2022, then tumbled by 63848.93% to -$509.7 million in 2023, then decreased by 1.91% to -$519.4 million in 2024, then soared by 100.03% to $174000.0 in 2025, then plummeted by 394.83% to -$513000.0 in 2026.
  • Business Quant data shows Retained Earnings for FULC at -$513000.0 in Q1 2026, $174000.0 in Q4 2025, and $241000.0 in Q3 2025.